Conference Reports for NATAP

Back

XV International AIDS Conference in Bangkok July 11-16, 2004                 Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (08/30/04)   Passive Immunotherapy Drug: HRG214 - (08/17/04)   NEW NNRTI 695634: safety, PK, tolerability in healthy subjects - (08/17/04)   RE-EXAMINING WHEN TO BEGIN HIV THERAPY & D4T USE & LIPOATROPHY - (08/17/04)   UK-427,857, a new CCR5 (entry) Inhibitor: viral load, safety QTc interval, tolerability, food effect in 10 day monotherapy study - (08/17/04)   Lopinavir/ritonavir (LPV/r) Safety, Tolerability and Efficacy & Liver Safety in Hep C and/or Hep B-infected Patients: Review of Kaletra Trials - (08/17/04)   Extensive Resistance Testing During 5 Years of Lopinavir/ritonavir Treatment in Antiretroviral-Naive HIV-infected Patients: Results from Study 720 - (08/06/04)   Once Daily Kaletra plus Tenofovir & FTC: PK, resistance, antiviral activity - (08/05/04)   PHARMACOKINETIC INTERACTIONS OF ATAZANAVIR AND SAQUINAVIR IN ARITONAVIR BOOSTED DOUBLE-PROTEASE INHIBITOR THERAPY REGIMEN: ATSAQ Cohort Study - (08/04/04)   Risk of Metabolic Syndrome (MetSyn) Among Highly Treatment-Experienced HIV-Infected Patients -- 48 Week Results from BMS Study AI424-045 - (07/29/04)   Higher Doses of Lopinavir/ritonavir (LPV/r) in Highly Treatment-Experienced, HIV-Infected Patients: 48-Week Safety/Efficacy Evaluation - (07/27/04)   8 Studies at IAC Bangkok on Tenofovir Renal Safety - (07/27/04)   Efavirenz (Sustiva)-Based HAART: 168 Weeks of Follow-Up (3-4 yrs) of original 006 EFV pivotal Study - (07/27/04)   Early 12-Week Viral Response in HCV/HIV Coinfection Predicts Sustained Viral Response (SVR) in APRICOT Study - (07/26/04)   Factors That Predict Response to Pegasys + Ribavirin (Copegus) in HCV/HIV Co-infection in the APRICOT Study - (07/26/04)   Changes in Body Fat on Reyataz & Sustiva - (07/26/04)   908/r: 48 WEEK RESULTS in PI-EXPERIENCED (CONTEXT STUDY) - (07/22/04)   IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)   Mitochondrial DNA depletion in HIV-infected patients is enhanced with chronic hepatitis C and treatment with pegylated interferon plus ribavirin - (07/22/04)   908/r QD in Treatment-Naïve 96 weeks Followup of SOLO - (07/22/04)   Safety of Pegasys Plus Ribavirin in HIV/HCV Co-infection (APRICOT STUDY) - (07/20/04)   SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients - (07/20/04)   Lipids Changes in Reyataz Expanded Access Program - (07/20/04)   Tenofovir vs d4T + EFV/3TC, study 903: 144 weeks in men & women - (07/19/04)   Adefovir for HBV/HIV Coinfection with 3TC Resistance: 4 years followup - (07/19/04)   ONCE DAILY PI REGIMEN 1600/100 SQV-hgc/r: 24 week results - (07/19/04)   Single-drug HAART (Lopinavir/r) for maintenance of HIV viral suppression - (07/19/04)   Treatment Interruption Studies at Bangkok IAC - (07/19/04)   High prevalence and late diagnosis of HIV among Black men aged 40-54 in New York City - (07/16/04)   Lopinavir/ritonavir- versus efavirenz-based therapy as the two first-line HAART regimens for naive HIV-infected subjects - (07/16/04)   Safety and tolerability of vaginal tenofovir gel (TFV) in HIV-uninfected and HIV-infected women (HPTN 050) - (07/16/04)   Peter Piot, UNAIDS, Plenary Address for Closing Ceremony - (07/16/04)   Effect on Glucose Metabolism by Adding Lo-Dose RTV to Reyataz: In Vitro study - (07/16/04)   HCV Coinfection May Affect CD4 Response to HAART - (07/16/04)   PA-457, New HIV Drug; & Research for new Fusion Inhibitors - (07/16/04)   BANGKOK: Reyataz/rtv Approved for Treatment-Experienced; Once Daily PI Regimen- Invirase/rtv (1600/100mg), pilot study results - (07/16/04)   Simplification from HAART to Kaletra Monotherapy: 2 pilot studies - (07/16/04)   BANGKOK IAC Daily Highlights, Thurs July 17: microbicides, Global AIDS, treatment in Thailand - (07/15/04)   BANGKOK INTL AIDS CONFERENCE: Daily Highlights - (07/15/04)   NEW FUZEON STUDY RESULTS: 2 years follow-up - (07/14/04)   FUZEON & FOSAMPRENAVIR STUDY RESULTS - (07/13/04)   KALETRA MONOTHERAPY - (07/13/04)   New NRTI Reverset for Patients with Nuke Resistance and in Treatment naive: 10-day monotherapy studies - (07/13/04)   REPORT FROM BANGKOK - (07/12/04)   New Pegasys Study data: 43% of non-responders have histological improvement - (07/12/04)   U.S. Works As Vietnam Ally in War on AIDS - (07/12/04)   Asian AIDS crisis, prevention in focus at Bangkok - (07/09/04)   UPDATE on SCHERING'S PLOUGH'S ENTRY INHIBITOR (CCR5 Inhibitor) IN PHASE II CLINICAL DEVELOPMENT - (07/09/04)   ON THE ROAD TO BANGKOK: HIV IN THAILAND & ASIA—the latest information out today - (07/08/04)   UNAIDS Full Executive Summary 2004 Report on the global AIDS epidemic - (07/07/04)   Global HIV/AIDS & ASIA - (07/07/04)   Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? - (07/06/04)   HIV/AIDS in Asia - (07/06/04)   Generic HAART Studied in Cameroon: d4T/NVP/3TC, 80% <400 copies/ml - (07/06/04)